SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

High global consumption of potentially inappropriate fixed dose combination antibiotics: Analysis of data from 75 countries

Bortone, B; Jackson, C; Hsia, Y; Bielicki, J; Magrini, N; Sharland, M (2021) High global consumption of potentially inappropriate fixed dose combination antibiotics: Analysis of data from 75 countries. PLoS One, 16 (1). e0241899. ISSN 1932-6203 https://doi.org/10.1371/journal.pone.0241899
SGUL Authors: Hsia, Yingfen Bielicki, Julia Anna Sharland, Michael Roy

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (598kB) | Preview
[img] Microsoft Word (.docx) (S1 Table) Published Version
Available under License Creative Commons Attribution.

Download (29kB)
[img] Microsoft Word (.docx) (S2 Table) Published Version
Download (14kB)
[img] Microsoft Word (.docx) (S3 Table) Published Version
Available under License Creative Commons Attribution.

Download (17kB)
[img] Microsoft Word (.docx) (S4 Table) Published Version
Available under License Creative Commons Attribution.

Download (14kB)
[img] Microsoft Word (.docx) (S5 Table) Published Version
Available under License Creative Commons Attribution.

Download (14kB)
[img] Microsoft Word (.docx) Accepted Version
Available under License Creative Commons Attribution.

Download (103kB)
[img] Microsoft PowerPoint (Figure 1) Accepted Version
Available under License Creative Commons Attribution.

Download (1MB)
[img] Microsoft Word (.docx) (Supplemental tables) Accepted Version
Download (42kB)

Abstract

Antibiotic fixed dose combinations (FDCs) can have clinical advantages such as improving effectiveness and adherence to therapy. However, high use of potentially inappropriate FDCs has been reported, with implications for antimicrobial resistance (AMR) and toxicity. We used a pharmaceutical database, IQVIA-Multinational Integrated Data Analysis System (IQVIA-MIDAS®), to estimate sales of antibiotic FDCs from 75 countries in 2015. Antibiotic consumption was estimated using standard units (SU), defined by IQVIA as a single tablet, capsule, ampoule, vial or 5ml oral suspension. For each FDC antibiotic, the approval status was assessed by either registration with the United States Food and Drug Administration (US FDA) or inclusion on the World Health Organization (WHO) Essential Medicines List (EML). A total of 119 antibiotic FDCs were identified, contributing 16.7 x 109 SU, equalling 22% of total antibiotic consumption in 2015. The most sold antibiotic FDCs were amoxicillin-clavulanic acid followed by trimethoprim/sulfamethoxazole and ampicillin/cloxacillin. The category with the highest consumption volume was aminopenicillin/β-lactamase inhibitor +/- other agents. The majority of antibiotic FDCs (92%; 110/119) were not approved by the US FDA. Of these, the most sold were ampicillin/cloxacillin, cefixime/ofloxacin and metronidazole/spiramycin. More than 80% (98/119) of FDC antibiotics were not compatible with the 2017 WHO EML. The countries with the highest numbers of FDC antibiotics were India (80/119), China (25/119) and Vietnam (19/119). There is high consumption of FDC antibiotics globally, particularly in middle-income countries. The majority of FDC antibiotic were not approved by either US FDA or WHO EML. International initiatives such as clear guidance from the WHO EML on which FDCs are not appropriate may help to regulate the manufacturing and sales of these antibiotics.

Item Type: Article
Keywords: General Science & Technology, MD Multidisciplinary
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: PLoS One
ISSN: 1932-6203
Dates:
DateEvent
20 January 2021Published
22 October 2020Accepted
Publisher License: Creative Commons: Attribution 4.0
URI: https://openaccess.sgul.ac.uk/id/eprint/112530
Publisher's version: https://doi.org/10.1371/journal.pone.0241899

Actions (login required)

Edit Item Edit Item